
Welcome to DIALOG

Dialog level 99.04.12D

Last logoff: 14apr99 08:39:25

Logon file001 26apr99 08:27:19

ANNOUNCEMENT **** ANNOUNCEMENT **** ANNOUNCEMENT
NEW

***Miller Freeman Industry and Product News (File 112)

***Irish Times (File 477)

***Business Wire (Files 610 for current news & 810 for archive news)

***Financial Times Abstracts (File 473)

RELOADED

***Kompass Western Europe (File 590)

***HealthSTAR (File 151)

***Aidsline (File 157)

***Medline (Files 154,155)

***EMBASE (Files 72,73)

DIALINDEX

***DIALINDEX categories have been revised. For listing of new/revised
categories see <http://library.dialog.com/bluesheets/html/blo.html>.
For more details, see HELP NEWS411.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

□dialog

>>> of new databases, price changes, etc. <<<

***** The DIALORDER suppliers DYNAMIC and FILEDOC are no longer *****
***** in business. Please do not use them. *****

***** File 265: Please use file 266 as file 265 is no longer *****
***** available. *****

***** The MASIS DIALORDER service has been discontinued. For *****
***** details, please contact MARUZEN CO. LTD, at 3-3272-3496. *****

***** Files 100 and 552 have been removed from DIALOG. *****

File 1:ERIC 1966-1999/Apr

(c) format only 1999 The Dialog Corporation

*File 1: In 1999, RIE and CIJE sections will be added separately,
as soon as they arrive. UDs may be irregular. UD codes will change.

Set Items Description

--- ----

? b 410

>>>'IALOG' not recognized as set or accession number
? set hi ;set hi'

26apr99 08:27:27 User208760 Session D1218.1

\$0.29 0.090 DialUnits File1

\$0.29 Estimated cost File1

FTSNET 0.016 Hrs.
\$0.29 Estimated cost this search
\$0.29 Estimated total session cost 0.090 DialUnits

File 410:Chronolog(R) 1981-1999 Mar/Apr
(c) 1999 The Dialog Corporation plc

Set Items Description
--- -----

?

HILIGHT set on as ''

HILIGHT set on as ''

? begin 55,72,154,399,357

26apr99 08:27:45 User208760 Session D1218.2
\$0.00 0.042 DialUnits File410
\$0.00 Estimated cost File410
FTSNET 0.005 Hrs.
\$0.00 Estimated cost this search
\$0.29 Estimated total session cost 0.132 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 55:BIOSIS PREVIEWS(R) 1993-1999/Apr W4
(c) 1999 BIOSIS

*File 55: File is reloaded. Accession number changed.

File 72:EMBASE 1993-1999/Apr W3
(c) 1999 Elsevier Science B.V.

*File 72: EMBASE reloaded. Accession numbers have changed.

File 154:MEDLINE(R) 1993-1999/Jun W3
(c) format only 1999 Dialog Corporation

*File 154: reloaded, note accession numbers changed.

File 399:CA SEARCH(R) 1967-1999/UD=13017
(c) 1999 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.

RANK charge added; see HELP RATES 399.

File 357:Derwent Biotechnology Abs 1982-1999/Apr B2
(c) 1999 Derwent Publ Ltd

*File 357: Effective October 1, DialUnit rates adjusted for unrounding.
See HELP NEWS 357 for details.

Set Items Description
--- -----

? e au=martin, ulrich ?

Ref	Items	Index-term
E1	0	*AU=MARTIN, ULRICH ?
E2	1	AU=MARTIN, ULRIKE
E3	1	AU=MARTIN, ULY
E4	1	AU=MARTIN, UNA
E5	1	AU=MARTIN, UNIE D.
E6	4	AU=MARTIN, UNJA
E7	1	AU=MARTIN, URSULA
E8	44	AU=MARTIN, V.
E9	4	AU=MARTIN, V. A.
E10	1	AU=MARTIN, V. B.
E11	1	AU=MARTIN, V. DEL C.
E12	1	AU=MARTIN, V. DEL. C.

Enter P or PAGE for more

? s (selectin?) and (antibod?) and (extracorporeal or (heart(w)lung or polytrauma?)

>>>Unmatched parentheses

? s (selectin?) and (antibod?) and (extracorporeal or heart(w)lung or polytrauma?)

33906 SELECTIN?
 606098 ANTIBOD?
 18202 EXTRACORPOREAL
 549064 HEART
 312827 LUNG
 4778 HEART(W) LUNG
 1048 POLYTRAUMA?
 S1 24 (SELECTIN?) AND (ANTIBOD?) AND (EXTRACORPOREAL OR
 HEART(W) LUNG OR POLYTRAUMA?)
 ? rd s1
 ...completed examining records
 S2 16 RD S1 (unique items)
 ? t s2/7/all

2/7/1 (Item 1 from file: 55)
 DIALOG(R)File 55:BIOSIS PREVIEWS(R)
 (c) 1999 BIOSIS. All rts. reserv.

11576580 BIOSIS NO.: 199800357276
 Measurement of platelet activation and adhesion to leukocytes during
 haemodialysis.

AUTHOR: Vickers J; Loesche W; Doepel E; Heptinstall S; Stein G; Spangenberg
 P(a)
 AUTHOR ADDRESS: (a)Univ. Applied Sci. Jena, Fac. Med. Eng.,
 Tatzendpromenade 1b, 07745 Jena, Germany

JOURNAL: Platelets (Abingdon) 9 (3-4):p261-264 1998
 ISSN: 0953-7104
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

ABSTRACT: In this study we used fluorescent-labelled **antibodies** to
 measure the extent of platelet adhesion to polymorphonuclear leukocytes
 (PMNLs), monocytes and lymphocytes. The activation of platelets, PMNLs
 and monocytes were also measured during the course of hemodialysis
 treatment using flow cytometric techniques established in our laboratory.
 Twenty patients were treated with either a cellulose membrane (TFU) or a
 polycarbonate filter (Pro 500). Blood samples were taken from the output
 line of the dialyzer 2, 15, 30 and 180 min after commencing dialysis and
 just before starting treatment. Compared with the pre-dialysis sample,
 there was a marked increase in platelet-PMNL conjugate formation at 2
 min, followed by a decrease in conjugates at 15 and 30 min, and a slight
 increase at 180 min. During **extracorporeal** circulation PMNLs become
 activated as measured by a CD11b upregulation at 15, 30 and 180 min, but
 not at 2 min. Platelet binding to monocytes was increased above 15 min
 after starting dialysis, and monocyte activation was slightly increased
 above basal levels during the same period. The activation state of
 circulating free platelets, as measured by surface P-**selectin**
 exposition, initially decreased slightly, but then returned to basal
 levels over the 3-h period. Changes in cell counts were also detected:
 there was a massive decrease in circulating PMNLs and monocytes, and a
 small decrease in circulating platelets, at 15 and 30 min. These reverted
 to basal values by the end of the 3-h period. There was no change in
 the number of circulating lymphocytes or erythrocytes. These results show
 that flow cytometric studies on whole blood samples may provide important
 information on the behaviour of circulating blood cells, which could
 supplement conventional clinical measurements, to give a better insight
 into changes that occur in the circulation during hemodialysis.

2/7/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

10273264 BIOSIS NO.: 199698728182
Amplification of the inflammatory response: Adhesion molecules associated with platelet/white cell responses.

AUTHOR: Rinder Christine(a); Fitch Jane
AUTHOR ADDRESS: (a)Dep. Anesthesia, Yale University, 333 Cedar Street, PO Box 3333, New Haven, CT 06510, USA

JOURNAL: Journal of Cardiovascular Pharmacology 27 (SUPPL. 1):pS6-S12 1996
ISSN: 0160-2446
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Cardiopulmonary bypass (CPB) causes leukocyte and platelet activation, resulting in upregulation of the adhesion receptor CD11b/CD 18 on leukocytes and upregulation of P-selectin, the adhesion receptor that binds the activated platelet to polymorphonuclear neutrophils (PMNs) and monocytes. Our laboratory has studied the expression of activation-dependent adhesion receptors during in vivo CPB. Both PMN and monocyte CD11b were upregulated during CPB but with differing time courses. Peak PMN CD11b levels occurred at the end of the hypothermic phase of bypass, whereas monocyte CD11b levels increased steadily throughout the course of CPB, peaked at 2-4 h after CPB, and remained significantly elevated as late as 18-24 h post CPB. The percentage of P-selectin-positive platelets increased significantly during bypass, peaking around the end of bypass and remaining elevated in the early post-bypass period. The level then returned to normal by 18 h post-bypass. Monocyte-platelet binding paralleled the increase in P-selectin-positive platelets during bypass and similarly remained elevated in the post-bypass period. PMN-platelet binding also increased but peaked early during CPB. Upregulation of these adhesive receptors and formation of platelet-leukocyte conjugates may influence the prothrombotic activity of monocytes and the proinflammatory activity of PMNs in the post-CPB period. Our laboratory has developed an in vitro model of extracorporeal circulation, and recirculation of blood on this circuit results in significant activation of PMNs and monocyte CD11b expression, increasing progressively over time. Likewise, the percentage of P-selectin-positive platelets increased and was paralleled by the formation of leukocyte-platelet conjugates comparable to the pattern found in vivo. Generation of the complement fragments C5a and the C5b-9 membrane-attack complex may contribute to platelet P-selectin expression and formation of leukocyte-platelet conjugates during CPB. The in vitro model has been used to test the cellular effects of complement inhibition employing a monoclonal antibody that blocks cleavage of C5 into C5a and C5b to determine the role of early vs. late complement components in the cellular activation induced by CPB. Preliminary results demonstrate that blockade of the formation of C5a and the C5b-9 membrane-attack complex during simulated extracorporeal circulation effectively inhibits platelet and PMN activation and the formation of leukocyte-platelet conjugates.

2/7/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

10104512 BIOSIS NO.: 199698559430
Studies of the effect of Pall leucocyte filters LG6 and AV6 in an in vitro simulated extracorporeal circulatory system.

AUTHOR: Thurlow P J(a); Doolan L; Sharp R; Sullivan M; Smith B
AUTHOR ADDRESS: (a)Haematology Dep., Austin Hosp., Studley Road,
Heidelberg, VIC 3084, Australia

JOURNAL: Perfusion 10 (5):p291-300 1995
ISSN: 0267-6591
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Neutrophil activation is thought to play a major role in the inflammatory response seen in reperfusion injury and similar clinical situations, i.e. **extracorporeal** circulation. Impairment of neutrophil function or reduction of total numbers of neutrophils using a leucocyte filter may be beneficial in reducing the adverse clinical effects. In this study, we have investigated the effect of the Pall LG6 and control AV6 filters during simulated in vitro cardiopulmonary bypass (CPB). Various parameters were evaluated including neutrophils, total leucocytes, monocytes, lymphocytes and platelets, expression of antigens on neutrophils using a panel of leucocyte-associated monoclonal **antibodies** CD13, 14, 15, 45Ro, 67, 11a, 11b and L **selectin**. The effects of leucocyte stimulation with phorbol myristate acetate (PMA) and a leucocyte bolus from a patient with chronic myeloid leukaemia (CML) were also investigated. We have demonstrated that the LG6 significantly reduces leucocytes, in particular neutrophils, with a modest reduction of lymphocytes, platelets and haematocrit, whereas the AV6 had no effect on leukocytes or neutrophils in the test system. In addition the LG6 was associated with a reduction in expression of all leucocyte antigens by approximately 20%; however there was no appreciable alteration of any of the antigens with AV6. Leucocyte stimulation with PMA resulted in a dramatic decrease of all cellular elements and an extra leucocyte load (using CML leucocytes) was not effectively filtered by the LG6 filter.

2/7/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

10039056 BIOSIS NO.: 199598493974
Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during **extracorporeal** circulation.

AUTHOR: Rinder Christine S(a); Rinder Henry M; Smith Brian R; Fitch Jane C
K; Smith Michael J; Tracey Jayne B; Matis Louis A; Squinto Stephen P;
Rollins Scott A
AUTHOR ADDRESS: (a)Dep. Anesthesiol., Tompkins 3, Yale Univ. Sch. Med., 333
Cedar St., New Haven, CT 06510, USA

JOURNAL: Journal of Clinical Investigation 96 (3):p1564-1572 1995
ISSN: 0021-9738
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Complement activation contributes to the systemic inflammatory response induced by cardiopulmonary bypass. At the cellular level, cardiopulmonary bypass activates leukocytes and platelets; however the contribution of early (C3a) versus late (C5a, soluble C5b-9) complement components to this activation is unclear. We used a model of simulated **extracorporeal** circulation that activates complement (C3a, C5a, and C5b-9 formation), platelets (increased percentages of P-**selectin** -positive platelets and leukocyte-platelet conjugates), and neutrophils (upregulated CD11b expression). To specifically target complement activation in this model, we added a blocking mAb directed at the human C5 complement component and assessed its effect on complement and

cellular activation. Compared with a control mAb, the anti-human C5 mAb profoundly inhibited C5a and soluble C5b-9 generation and serum complement hemolytic activity but had no effect on C3a generation. Additionally, the anti-human C5 mAb significantly inhibited neutrophil CD11b upregulation and abolished the increase in P-selectin-positive platelets and leukocyte-platelet conjugate formation compared to experiments performed with the control mAb. This suggests that the terminal components C5a and C5b-9, but not C3a, directly contribute to platelet and neutrophil activation during **extracorporeal** circulation. Furthermore, these data identify the C5 component as a site for therapeutic intervention in cardiopulmonary bypass.

2/7/5 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07159366 EMBASE No: 1998049901

Blockade of P-selectin downregulates free radicals and neutrophil migration without significant suppression of cytokines
Garcia-Criado F.J.; Palma-Vargas J.M.; Valdunciel-Garcia J.J.; Toledo A.H.; Misawa K.; Phillips M.L.; Gomez-Alonso A.; Toledo-Pereyra L.H.
Dr. L.H. Toledo-Pereyra, Surgical Research Institute, Borgess Medical Center, Stryker Center B Third Floor, 1521 Gull Rd, Kalamazoo, MI 49001 United States

AUTHOR EMAIL: mtisri@iserv.net
Transplantology: Journal of Cell and Organ Transplantation (TRANSPLANT. J. CELL ORGAN TRANSPLANT.) (Spain) 1997, 8/3 (79-86)

CODEN: TANSE ISSN: 1134-315X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 31

Background. Successful blockade of p-selectin has been demonstrated to protect organs from the neutrophil-dependent injury seen in ischemia/reperfusion. However, its possible role in the regulation of other inflammatory mediators has not been thoroughly studied. Thus, the purpose of this study was to determine the effect of P-selectin on the response of tissue free-radicals and serum cytokines after liver ischemia/reperfusion, in addition to its well known blockade of neutrophil migration. Material and methods. Total hepatic ischemia was produced in the rat for 90 minutes using an **extracorporeal** portosystemic shunt. The animals (n = 122) were divided into four groups including normal rats for reference values (group 1), sham-operated rats (group 2), ischemic control rats that received only the vehicle (group 3) and rats treated with PB1.3, a monoclonal **antibody** against P-selectin, at a dose of 1 mg/kg body wt i.v., 30 minutes before reperfusion (group 4). Animal survival was followed up to day 7 and liver function tests, determination of liver tissue free radicals and myeloperoxidase (MPO), assessment of serum cytokines (interleukin 1 and tumor necrosis factor) and liver histology were performed four hours after reperfusion. Results. Seven-day survival was significantly improved from only 20% in the control group to 65% in the PB1.3-treated group (p < 0.01). Liver function tests, histology and MPO tissue values were also significantly improved by treatment (p < 0.05). Furthermore, a significant downregulation of liver tissue free radicals was observed with the administration of PB1.3. Surprisingly, the anti-P-selectin monoclonal **antibody** did not significantly affect serum cytokine levels in comparison to controls. Conclusion. This data supports the existence of a protective mechanism for monoclonal **antibody** PB1.3 characterized by its ability to down regulate free radical levels in livers subjected to severe ischemia and reperfusion. As expected, the role of PB1.3 as a potent inhibitor of tissue neutrophil migration was confirmed, although the **antibody** did not affect the response of interleukin 1 or tumor necrosis factor to ischemia/reperfusion.

2/7/6 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07069410 EMBASE No: 1997351273

Effect of methylprednisolone on the oxidative burst activity, adhesion molecules and clinical outcome following open heart surgery
Toft P.; Christiansen K.; Tonnesen E.; Nielson C.H.; Lillevang S.
Dr. P. Toft, Dept. Anaesthesiology Intensive Care, University Hospital of Arhus, Arhus Kommunehospital, Norrebrogade 44, DK-8000 Arhus C Denmark
Scandinavian Cardiovascular Journal (SCAND. CARDIOVASC. J.) (Norway)
1997, 31/5 (283-288)

CODEN: SCJOF ISSN: 1401-7431
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 23

Following cardiac surgery with cardiopulmonary bypass (CPB), activated granulocytes may be involved with ischaemia/reperfusion injury. The purpose of this study was to investigate whether steroids could reduce the oxidative burst activity of granulocytes, the expression of adhesion molecules on granulocytes and improve clinical outcome. Sixteen patients undergoing open heart surgery participated in the study. Eight were randomized to receive methylprednisolone (30 mg/kg intravenously) at the start of anaesthesia while eight patients served as a control group. The oxidative burst was measured flow cytometrically using 123-dihydrorhodamine. A panel of adhesion molecules was measured using monoclonal **antibodies**. Following CPB the oxidative burst activity and the expression of the adhesion molecule **L-selectin** more than doubled compared to initial values. There was no difference between the steroid group and the control group regarding the expression of adhesion molecules or the oxidative burst activity. In the steroid group the fluid gain during **extracorporeal** circulation (ECC) was 683 ml (median) compared to 1488 ml in the control group. Steroids prevented hyperthermia in the postoperative period but did not improve the weaning from the ventilator or reduce the stay in the intensive-care unit. In conclusion, treatment with steroids prevented hyperthermia following open heart surgery with CPB and reduced capillary leak during ECC. Methylprednisolone, however, did not reduce the oxidative burst activity or the expression of adhesion molecules on granulocytes following CPB.

2/7/7 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07063418 EMBASE No: 1997345281

Modulation of surface platelet membrane receptors in patients with coronary artery disease during cardiopulmonary bypass - A preliminary report
Golanski R.; Golanski J.; Watala C.; Chizynski K.; Chrul S.; Zochniak J.; Iwaszkiewicz A.

R. Golanski, Hosp. Dept. Anesthesiol/Intens. Care, Institute of Cardiology, Lodz Poland
Medical Science Monitor (MED. SCI. MONIT.) (Poland) 1997, 3/4
(437-445)

CODEN: MSMOF ISSN: 1234-1010
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33

The nature of the supposed effects of cardiopulmonary bypass (CPB) on defects in platelet function remains controversial, however, cardiac surgery is believed to be associated with a disruption of the haemostatic system. We employed whole blood flow cytometry to evaluate the possible alterations in the expression of platelet surface membrane glycoproteins in resting and thrombin- or ADP-activated platelets in peripheral blood. As monitored by the use of monoclonal **antibodies** directed against glycoproteins GPIb, GPIIIa, GPIIb/IIIa complexes and P-selectin, circulating blood platelets subjected to **extracorporeal** circulation were characterized by: a/ time-dependent increase in platelet surface P-selectin, b/ paralleled marked reductions in GPIb and GPIIIa, c/ increased microparticle fraction with no platelet clumping. In comparison to circulating blood platelets collected during CPB, the alterations in platelet P-selectin in post-surgery blood (20 h after bypass) were negligible. We observed the loss in platelet reactivity at every time point of CPB, both in response to time-driven spontaneous anticoagulant-induced activation and following the in vitro action of thrombin and ADP; these depressions occurred with respect to all the monitored platelet surface antigens and remained least marked in post-surgery blood. Our results seem to furnish support for a novel outlook on the molecular mechanisms of the altered expression of platelet surface membrane receptors during CPB. We suggest that (1) markedly deficient platelet reactivity in response to agonist-induced platelet activation, (2) loss of platelet surface membrane glycoproteins GPIb and GPIIIa, (3) enhanced expression of surface membrane P-selectin, and (4) increased number of platelet microparticles point to platelet increased consumption/rupture, degranulation, membrane protein shedding, or all of the above effects as major contributors to altered expression of platelet membrane receptors in CPB patients. Noteworthy, a markedly depressed number/expression of platelet fibrinogen receptor, which, in turn, became augmented in post-surgery blood, implies that CPB can make peripheral blood platelets more vulnerable to pro-aggregatory action of agonists in vivo. This last observation seems critical since it validates the suspicion of the enhanced risk for early occlusion of vein bypass grafts in patients undergoing coronary artery surgery.

2/7/8 (Item 4 from file: 72)
 DIALOG(R) File 72:EMBASE
 (c) 1999 Elsevier Science B.V. All rts. reserv.

06263839 EMBASE No: 1995300293
 Platelet membrane glycoproteins and microvesicles in blood from postoperative salvage: A study in cardiac bypass patients
 Sloan E.; Alyono D.; Yu M.; Klein H.
 NHLBI, Building 31, MSC 2490, 31 Center Drive, Bethesda, MD 20892-2490
 United States
 Transfusion (TRANSFUSION) (United States) 1995, 35/9 (738-744)

CODEN: TRANA ISSN: 0041-1132
 DOCUMENT TYPE: Journal; Article
 LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Background: Transfusion of blood collected by intraoperative and postoperative salvage systems has been linked to the development of thrombocytopenia and disseminated intravascular coagulation. Although functional defects have been reported in platelets from unwashed salvaged blood, platelet membrane glycoprotein (GP) composition, a potentially important determinant of function and survival, has not been studied. Study Design and Methods: Platelets from 22 patients whose blood was salvaged at the completion of surgery were analyzed and compared to platelets obtained from the venous blood from the same patient. Platelet membranes were stained with fluorescein isothiocyanate-conjugated CD41a monoclonal **antibody** (anti- GPIIb/IIIa) to identify platelets, a phycoerythrin-conjugated monoclonal **antibody**, CD62 (anti-P-selectin) to identify activated platelets, and CD42b (anti-GPIb) or

anti-GPIb/IX to assess GPIb. Samples were analyzed with a flow cytometer using software. Results: Platelets obtained from salvaged blood demonstrated lower GPIb expression (CD42b and GPIb/IX monoclonal **antibody** binding), higher P-**selectin** expression, and greater numbers of platelet-derived microvesicles. Conclusion: The clinical significance of transfusing blood containing activated platelets and microvesicles merits investigation.

2/7/9 (Item 1 from file: 154)
DIALOG(R) File 154:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

09285012 97467045

Small-molecule **selectin** inhibitor protects against liver inflammatory response after ischemia and reperfusion.

Palma-Vargas JM; Toledo-Pereyra L; Dean RE; Harkema JM; Dixon RA; Kogan TP

Surgical Research Institute at Borgess Medical Center, Kalamazoo, MI 49001, USA.

J Am Coll Surg (UNITED STATES) Oct 1997, 185 (4) p365-72, ISSN 1072-7515 Journal Code: BZB

Languages: ENGLISH

Document type: JOURNAL ARTICLE

BACKGROUND: The **selectin** family of adhesion molecules plays a key role in the neutrophil-mediated injury observed after ischemia and reperfusion. In our study, we investigated the effects of TBC-1269, a novel small-molecule, nonoligosaccharide inhibitor of P-, E-, and L-**selectin** binding, in the liver inflammatory response after 90 minutes of warm ischemia. STUDY DESIGN: Total liver ischemia was produced in Sprague-Dawley rats for 90 minutes using an **extracorporeal** portosystemic shunt. The animals were divided into five groups including: the sham (group 1), ischemic control (group 2) receiving only the vehicle, and the treated groups receiving TBC-1269 at a dose of 25 mg/kg at different times of administration: 15 minutes before reperfusion (group 3), at reperfusion (group 4), and 15 minutes after reperfusion (group 5). The following indices were analyzed: 7-day survival, liver injury tests, liver tissue myeloperoxidase as an index of neutrophil infiltration, and liver histology. RESULTS: TBC-1269 treated groups experienced a significant increase in survival compared with controls. Best overall survival, 70%, was observed when TBC-1269 (Texas Biotechnology Corporation, Houston, TX) was administered 15 minutes before reperfusion ($p < 0.05$). This group also showed a marked decrease ($p < 0.05$) in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration was also significantly ameliorated (81%), as reflected by decreased myeloperoxidase levels. We observed improved histologic damage scores in the treated group compared with controls ($p < 0.05$). CONCLUSIONS: A small-molecule **selectin** inhibitor (TBC-1269) had a protective effect in livers subjected to 90 minutes of warm hepatic ischemia and 6 hours of reperfusion by decreasing neutrophil infiltration, migration and subsequent tissue damage. The best protective effect was achieved when the compound was administered 15 minutes before reperfusion. These findings offer a new therapeutic alternative for protection against ischemia and reperfusion injury.

2/7/10 (Item 2 from file: 154)
DIALOG(R) File 154:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

08994630 97207472

Effects of GP IIb/IIIa receptor monoclonal **antibody** (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.

Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S

Department of Medicine, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Circulation (UNITED STATES) Feb 18 1997, 95 (4) p1015-21, ISSN 0009-7322 Journal Code: DAW

Languages: ENGLISH

Document type: JOURNAL ARTICLE

BACKGROUND: Thrombosis is an important limitation of metallic coronary stents, especially in smaller vessels in which shear rates are high. Monoclonal **antibody** to platelet glycoprotein IIb/IIIa receptor (7E3) has been shown to inhibit shear-induced platelet aggregation. In this study, we compared the effects of 7E3, heparin, and aspirin on stent thrombosis in an ex vivo arteriovenous shunt model of high-shear blood flow. **METHODS AND RESULTS:** An ex vivo arteriovenous shunt was created in 10 anesthetized dogs. Control rough-surface slotted-tube nitinol stents (n = 72) expanded to 2 mm in diameter in a tubular perfusion chamber were interposed in the shunt and exposed to flowing arterial blood at a shear rate of 2100s⁻¹ for 20 minutes. The animals were treated with intravenous murine 7E3 (Fab')₂ (0.2, 0.4, and 0.8 mg/kg), heparin (100 U/kg), or aspirin (10 mg/kg). Effects of the test agents on thrombus weight, platelet aggregation, platelet P-selectin expression, bleeding time, and activated clotting time (ACT) were quantified. 7E3 reduced stent thrombosis by 95% (20 +/- 1 to 1 +/- 1 mg, P < .001) and platelet aggregation by 94% (14 +/- 2 to 1 +/- 1 omega, P < .001) at the highest dose (0.8 mg/kg). 7E3 significantly prolonged bleeding time but had no effect on ACT and platelet P-selectin expression. Heparin prolonged ACT but had no significant effect on stent thrombosis or platelet aggregation. Aspirin, although it inhibited platelet aggregation by 65%, had no effect on stent thrombosis (19 +/- 2 versus 20 +/- 1 mg in controls). **CONCLUSIONS:** 7E3 produced a dose-dependent inhibition of acute stent thrombosis under high-shear flow conditions. Stent thrombosis was resistant to heparin and aspirin. Thus, 7E3 may be an effective agent for preventing stent thrombosis.

2/7/11 (Item 3 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

08609211 95202670

Neutrophil activation in paediatric **extracorporeal** circuits: effect of circulation and temperature variation.

el Habbal MH; Carter H; Smith LJ; Elliott MJ; Strobel S

Cardiothoracic Unit, Hospital for Sick Children, London, United Kingdom.

Cardiovasc Res (ENGLAND) Jan 1995, 29 (1) p102-7, ISSN 0008-6363

Journal Code: COR

Languages: ENGLISH

Document type: JOURNAL ARTICLE

OBJECTIVE: Upregulation of neutrophil adhesion molecules (CD11b and L-selectin) and release of a modulating cytokine (IL8) have been reported in vivo and in vitro in adult cardiopulmonary bypass. The aim of this study was to determine whether paediatric bypass preparations have similar influences and whether neutrophil-endothelium interactions are required for IL8 release. **METHODS:** In vitro paediatric cardiopulmonary bypass circuits (n = 15) were constructed (identical to those used clinically), as well as static loops (n = 15) using donor blood. The effects of circulation and temperature (17 degrees C, 25 degrees C, 37 degrees C) on the initiation of acute inflammation were examined. Cellular expressions of neutrophil adhesion molecules CD11b and L-selectin were assayed by immunofluorescence technique, and serum IL8, IL6, TNF-alpha, leucocyte elastase, and terminal complement complex were measured by ELISA. **RESULTS:** In all experiments, an immediate increase in CD11b expression occurred [median values, in relative fluorescence units: 64.9 (range 45.3-212.9) at rest; 365.2 (205-835.4) at 10 min; P < 0.001], along with a decrease in L-selectin expression [153.5 (115.5-220.7) at rest; 42 (12-134) at 10 min; P < 0.01]. Serum concentrations of the following increased gradually and were higher in circulation than in static

loops: IL8 [1500 (500-2500) pg.ml-1 in circuit v 600 (180-1500) pg.ml-1 in loop, P < 0.001]; TNF-alpha P < 0.05]; and terminal complement complex [25.9 (6.8-120) v 4.7 (0-21.6) AU.ml-1, P < 0.01]. Cooling decreased and rewarming increased upregulation of CD11b and downregulation of L-selectin and release of IL8. IL6 was undetectable. CONCLUSIONS: In the absence of endothelium, in vitro paediatric cardiopulmonary bypass causes profound acute inflammatory changes in donor blood with release of IL8. These changes were greater than in adult cardiopulmonary bypass. Temperature variation and circulation modulate the responses.

2/7/12 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

07806141 94091906
Humoral and cellular activation in a simulated **extracorporeal** circuit.
Moat NE; Rebuck N; Shore DF; Evans TW; Finn AH
Royal Brompton National Heart and Lung Hospital, London, England.
Ann Thorac Surg (UNITED STATES) Dec 1993, 56 (6) p1509-14, ISSN 0003-4975 Journal Code: 683
Languages: ENGLISH
Document type: JOURNAL ARTICLE
Endothelial injury consequent upon widespread humoral and cellular activation is probably a major contributor to the phenomenon of cardiopulmonary bypass-induced organ dysfunction. This article reviews some of the mechanisms by which complement and neutrophil activation, and interleukin-8 may be involved in this inflammatory response. In a model consisting of a simulated **extracorporeal** circulation we were able to demonstrate complement activation, profound and specific changes in neutrophil adhesion molecule expression, and interleukin-8 generation. The importance of these changes and their potential interactions are discussed.

2/7/13 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

128266260 CA: 128(22)266260q PATENT
Methods using selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
INVENTOR(AUTHOR): Pinsky, David J.; Stern, David; Schmidt, Ann Marie; Rose, Eric A.; Connolly, E. Sander; Solomon, Robert A.; Prestigiacomo, Charles J.
LOCATION: USA
ASSIGNEE: Trustees of Columbia University In the City of New York; Pinsky, David J.; Stern, David; Schmidt, Ann Marie; Rose, Eric A.; Connolly, E. Sander; Solomon, Robert A.; Prestigiacomo, Charles J.
PATENT: PCT International ; WO 9813058 A1 DATE: 19980402
APPLICATION: WO 97US17229 (19970925) *US 721447 (19960927)
PAGES: 230 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/00A; A61K-038/02B; A61K-038/17B; A61K-038/36B; A61K-039/395B; C07K-005/00B; C07K-014/00B; C07K-014/435B; C07K-014/745B; C07K-016/00B; C07K-016/18B; C07K-016/28B DESIGNATED COUNTRIES: AU; CA; JP; MX; US
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA201008 Pharmacology
CA214XXX Mammalian Pathological Biochemistry
CA263XXX Pharmaceuticals
IDENTIFIERS: antiischemic stroke selectin antagonist carbon monoxide, inactivated factor IX antiischemic stroke
DESCRIPTORS:
Leukocyte...

accumulation; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 E-selectin... L-selectin... P-selectin... Selectins...
 antagonists; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Methemoglobins...
 cyanometHbs; Hb spectrophotometric assay to quantify intracerebral hemorrhage
 Transient cerebral ischemia...
 focal; neutrophil adhesion role in stroke pathogenesis
 Cerebral hemorrhage... Spectrophotometry...
 Hb spectrophotometric assay to quantify intracerebral hemorrhage
 Surgery...
 heart; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Surgery...
 lung or other; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Transplant(organ)...
 lung; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Arterial diseases... Cerebral artery...
 middle cerebral artery occlusion; stroke outcome variability after permanent focal cerebral ischemia in relation to mouse strain and other variables
 ICAM-1(cell adhesion molecule)... Neutrophil adhesion... Polymorphonuclear leukocyte...
 neutrophil adhesion role in stroke pathogenesis
 Genes(animal)...
 P-selectin; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Organ preservation...
 P-selectin-dependent neutrophil adhesion role in hyperthermic/ischemic myocardial preservation
 Vascular diseases...
 peripheral; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Embolism...
 pulmonary; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Nervous system diseases...
 reversible ischemic neurol. deficit; selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Antithrombotics... Anti-ischemic agents... Extracorporeal circulation...
 Heart transplant... Inhalants(drug delivery systems)... Intravenous injections... Liver transplant... Lung ischemia... Monocyte... Myocardial infarction... Neutrophil... Oral drug delivery systems... Pancreas transplant... Platelet aggregation inhibitors... Platelet(blood)...
 Reperfusion injury... Sickle cell anemia... Sprays(drug delivery systems)
 ... Stroke... Topical drug delivery systems... Transient cerebral ischemia
 ... Transplant(organ)... Venous thrombosis...
 selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome
 Drug screening... Focal cerebral ischemia... Reperfusion...
 selectin antagonists, carbon monoxide, and inactivated factor IX for treating an ischemic disorder and improving stroke outcome, and anti-ischemic compd. identification method
 Carbohydrates,biological studies... Monosaccharides... Nucleic acids...

Oligosaccharides, biological studies... Peptidomimetics...
 Proteins (general), biological studies... Ribozymes...
 selectin antagonists; selectin antagonists, carbon monoxide, and
 inactivated factor IX for treating an ischemic disorder and improving
 stroke outcome
 Hypothermia... Mouse...
 stroke outcome variability after permanent focal cerebral ischemia in
 relation to mouse strain and other variables
 Heart...
 surgery; selectin antagonists, carbon monoxide, and inactivated factor
 IX for treating an ischemic disorder and improving stroke outcome
 Antibodies... Monoclonal antibodies...
 to selectins; selectin antagonists, carbon monoxide, and inactivated
 factor IX for treating an ischemic disorder and improving stroke
 outcome
 Focal cerebral ischemia...
 transient; neutrophil adhesion role in stroke pathogenesis
 Lung...
 transplant; selectin antagonists, carbon monoxide, and inactivated
 factor IX for treating an ischemic disorder and improving stroke
 outcome
 Angina pectoris...
 unstable; selectin antagonists, carbon monoxide, and inactivated factor
 IX for treating an ischemic disorder and improving stroke outcome
 Hypoxia (animal)... Vascular endothelium...
 von Willebrand's factor release and P-selectin translocation to cell
 surface with endothelial cell exposure to hypoxia
 Exocytosis...
 Weibel-Palade body exocytosis in cardiac surgery
 Organelle...
 Weibel-Palade body; Weibel-Palade body exocytosis in cardiac surgery
 CAS REGISTRY NUMBERS:
 10102-43-9 biological studies, agents stimulating; selectin antagonists,
 carbon monoxide, and inactivated factor IX for treating an ischemic
 disorder and improving stroke outcome
 630-08-0 biological studies, selectin antagonists, carbon monoxide, and
 inactivated factor IX for treating an ischemic disorder and improving
 stroke outcome
 9001-28-9P inactivated; selectin antagonists, carbon monoxide, and
 inactivated factor IX for treating an ischemic disorder and improving
 stroke outcome
 60-92-4 7665-99-8 pathway, agents stimulating; selectin antagonists,
 carbon monoxide, and inactivated factor IX for treating an ischemic
 disorder and improving stroke outcome
 37316-87-3 69024-84-6 reaction, in factor IXai prepn.; selectin
 antagonists, carbon monoxide, and inactivated factor IX for treating an
 ischemic disorder and improving stroke outcome
 55-63-0 31356-94-2 33876-97-0 selectin antagonists, carbon monoxide, and
 inactivated factor IX for treating an ischemic disorder and improving
 stroke outcome
 109319-16-6 von Willebrand's factor release and P-selectin translocation
 to cell surface with endothelial cell exposure to hypoxia

2/7/14 (Item 2 from file: 399)
 DIALOG(R) File 399:CA SEARCH(R)
 (c) 1999 American Chemical Society. All rts. reserv.

126263165 CA: 126(20)263165k PATENT
 Anti-selectin antibodies for prevention of multiple organ failure and
 acute organ damage
 INVENTOR(AUTHOR): Haselbeck, Anton; Schumacher, Guenther; Co, Man Sung;
 Martin, Ulrich
 LOCATION: USA
 ASSIGNEE: Protein Design Labs, Inc.; Boehringer Mannheim GmbH; Haselbeck,

Anton; Schumacher, Guenther; Co, Man Sung; Martin, Ulrich
PATENT: PCT International ; WO 9706822 A1 DATE: 19970227
APPLICATION: WO 96US13152 (19960814) *EP 95112895 (19950817) *EP 95114696
(19950919) *US 578953 (19951227)
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AL; AM; AU; BB; BG; BR; CA; CN; CU; CZ; EE; FI; GE;
HU; IL; IS; JP; KG; KP; KR; LK; LR; LT; LV; MD; MG; MK; MN; MX; NO; NZ; PL;
RO; SG; SI; SK; TR; TT; UA; US; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML;
MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

IDENTIFIERS: monoclonal antibody selectin multiple organ failure

DESCRIPTORS:

DNA sequences... Extracorporeal circulation... E-selectin...

Immunoglobulins... L-selectin... Monoclonal antibodies... Plasma(blood)...

Protein sequences... P-selectin... Selectins... Serum(blood)...

anti-selectin antibodies for prevention of multiple organ failure and
acute organ damage

Organ(animal)...

failure; anti-selectin antibodies for prevention of multiple organ
failure and acute organ damage

Antibodies...

humanized; anti-selectin antibodies for prevention of multiple organ
failure and acute organ damage

Organ(animal)...

injury, acute; anti-selectin antibodies for prevention of multiple
organ failure and acute organ damage

Diseases(animal)... Organ(animal)...

multiple organ failure; anti-selectin antibodies for prevention of
multiple organ failure and acute organ damage

Injury...

organ, acute; anti-selectin antibodies for prevention of multiple organ
failure and acute organ damage

Diseases(animal)...

organ failure; anti-selectin antibodies for prevention of multiple
organ failure and acute organ damage

Trauma...

poly-; anti-selectin antibodies for prevention of multiple organ
failure and acute organ damage

CAS REGISTRY NUMBERS:

188763-45-3 188763-47-5 amino acid sequence; anti-selectin antibodies for
prevention of multiple organ failure and acute organ damage
188763-44-2 188763-46-4 nucleotide sequence; anti-selectin antibodies for
prevention of multiple organ failure and acute organ damage

2/7/15 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

123078447 CA: 123(7)78447d PATENT

Human tissue inhibitor of metalloproteinase type three (TIMP-3), its
therapeutic uses and cloning of a cDNA encoding it

INVENTOR(AUTHOR): Silbiger, Scott M.; Koski, Raymond A.

LOCATION: USA

ASSIGNEE: Amgen Inc.

PATENT: European Pat. Appl. ; EP 648838 A1 DATE: 950419

APPLICATION: EP 94115578 (941004) *US 134231 (931006)

PAGES: 62 pp. CODEN: EPXXDW LANGUAGE: English CLASS: C12N-015/15A;
C07K-014/81B; C12N-001/21B; C12N-005/10B; A61K-048/00B; A61K-038/57B;
A61K-038/43B; A61K-038/17B; A61K-038/48B; C07K-016/38B

DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU;
MC; NL; PT; SE

SECTION:
CA207003 Enzymes
CA201XXX Pharmacology
IDENTIFIERS: TIMP3 cDNA human
DESCRIPTORS:
Plasmid and Episome,pCFM836...
cDNA for human TIMP-3 on; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Gene,animal...
cDNA; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Chemotactic factors...
chemoattractants, TIMP-3 and, in therapeutic compns.; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Embryo...
control of implantation of; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Extracellular matrix...
diseases assocd. with degrdn. of, treatment of; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Erythrocyte...
disorders of, TIMP-3 for treatment of; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Glycoproteins,specific or class, PAAG (pregnancy-assocd. .alpha.2-glycoprotein)... Lysosome... Macroglobulins,.alpha.2-...
enzymes of, TIMP-3 and, in therapeutic compns.; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Deoxyribonucleic acid sequences,complementary...
for TIMP-3 of human; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Fertilization,extracorporeal...
human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Adhesion,bio-...
modulators of, TIMP-3 and, in therapeutic compns.; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Protein sequences...
of TIMP-3 of human; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Surgery,cosmetic...
reconstructive; TIMP-3 in; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Animal growth regulators,blood platelet-derived growth factors... Animal growth regulators,brain-derived neurotrophic factors... Animal growth regulators,ciliary neurotrophic factors... Animal growth regulators,heregulins... Animal growth regulators,.beta.-transforming growth factors... Corticosteroids,gluco-,biological studies...
Glycophosphoproteins,E-selectins... Glycoproteins,specific or class, L-selectins... Hemopoietins,hematopoietic cell growth factors KL...
Integrins... Interferons... Lymphokines and Cytokines,chemokines...
Lymphokines and Cytokines,interleukins... Lymphokines and Cytokines,tumor necrosis factor-.alpha.... Retinoids...
TIMP-3 and, in therapeutic compns.; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Inflammation inhibitors... Neoplasm inhibitors... Ulcer inhibitors... Wound healing promoters...
TIMP-3 as; human tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Arthritis... Bone,disease... Connective tissue,disease, scleroderma...

Emphysema... Nerve,disease... Periodontium,disease... Skin,disease,
epidermolysis bullosa dystrophica...

TIMP-3 for treatment of; human tissue inhibitor of metalloproteinase
type 3 (TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Antibodies...

to human TIMP-3; human tissue inhibitor of metalloproteinase type 3
(TIMP-3), its therapeutic uses and cloning of cDNA encoding it
Deoxyribonucleic acids,complementary, antisense...

to TIMP-3 mRNA; human tissue inhibitor of metalloproteinase type 3
(TIMP-3), its therapeutic uses and cloning of cDNA encoding it

CAS REGISTRY NUMBERS:

156438-33-4D amino acid substituted analogs, amino acid sequence; human
tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic
uses and cloning of cDNA encoding it

165183-74-4 166586-12-5 antibodies to, of human TIMP-3; human tissue
inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic uses
and cloning of cDNA encoding it

145809-21-8 human tissue inhibitor of metalloproteinase type 3 (TIMP-3),
its therapeutic uses and cloning of cDNA encoding it

164781-48-0 nucleotide sequence; human tissue inhibitor of
metalloproteinase type 3 (TIMP-3), its therapeutic uses and cloning of
cDNA encoding it

9001-12-1 9001-90-5 9004-08-4 9032-92-2 9039-53-6 9041-92-3 9061-61-4
9087-70-1 11096-26-7 37184-63-7 37205-61-1 62031-54-3 62229-50-9
67763-96-6 67763-97-7 79955-99-0 81627-83-0 81669-70-7 86102-31-0
86697-40-7 124861-55-8 130939-66-1 138757-15-0 139639-23-9
140208-23-7 140610-48-6 141256-52-2 141436-78-4 142243-03-6
148263-58-5 148348-15-6 TIMP-3 and, in therapeutic compns.; human
tissue inhibitor of metalloproteinase type 3 (TIMP-3), its therapeutic
uses and cloning of cDNA encoding it

2/7/16 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 1999 Derwent Publ Ltd. All rts. reserv.

0183377 DBA Accession No.: 95-10198 PATENT

Extracorporeal blood treatment method - tumor-associated

ganglioside-specific monoclonal **antibody** production and hybridoma
cell culture

AUTHOR: Nudelman E; Singhal A; Clausen H; Hakomori S; Muroi K; Suda T;
Nojiri H

PATENT ASSIGNEE: Biomembrane-Inst.; Jichi-Med.Sch. 1995

PATENT NUMBER: US 5418129 PATENT DATE: 950523 WPI ACCESSION NO.:

95-205662 (9527)

PRIORITY APPLIC. NO.: US 803065 APPLIC. DATE: 911206

NATIONAL APPLIC. NO.: US 803065 APPLIC. DATE: 911206

LANGUAGE: English

ABSTRACT: An in vitro method of treating blood for transplantation
comprises exposing the blood to a therapeutically effective amount of
an **antibody** produced by (a) immunizing a host with tumor cells
expressing gangliosides; (b) boosting the host with a suspension
comprising a mixture of tumor cell membrane and at least one purified
lactonized tumor-associated ganglioside; (c) boosting the host with an
immunogen comprising a lactone to a tumor-associated ganglioside; (d)
fusing immunized cells from the host with myeloma cells to form
hybridoma cells; (e) **selecting** hybridoma cells producing a
monoclonal **antibody** that binds to the ganglioside of (c) and does
not react with hematopoietic progenitor cells; (f) culturing the
hybridoma cells; and (g) recovering the **antibody**. The monoclonal
antibody is SNH3 (ATCC HB-9941) or SNH4 (ATCC HB-10518). The
treatment may be used to purge myelogenous leukemia cells and blasts
from blood during bone marrow transplantation. (19pp)

? s (administrat? or dosage or dose?) and (antibod?) and (extracorporeal or
heart(w)lung or polytraum?)

Processing

747255 ADMINISTRAT?
257107 DOSAGE
645508 DOSE?
606098 ANTIBOD?
27 EXTRACOPREAL
549064 HEART
312827 LUNG
4778 HEART(W) LUNG
1048 POLYTRAUM?
S3 104 (ADMINISTRAT? OR DOSAGE OR DOSE?) AND (ANTIBOD?) AND
(EXTRACOPREAL OR HEART(W) LUNG OR POLYTRAUM?)

? rd s3

...examined 50 records (50)
...examined 50 records (100)
...completed examining records
S4 82 RD S3 (unique items)
? t s4/3/all

4/3/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

11788180 BIOSIS NO.: 199900034289
A stable prostacyclin analog, beraprost sodium, attenuates platelet
accumulation and preservation-reperfusion injury of isografts in a rat
model of lung transplantation.

AUTHOR: Okada Yoshinori; Marchevsky Alberto M; Kass Robert M; Matloff Jack
M; Jordan Stanley D(a)
AUTHOR ADDRESS: (a) Cedars-Sinai Med. Cent., 8700 Beverly Blvd., Los
Angeles, CA 90048, USA

JOURNAL: Transplantation (Baltimore) 66 (9):p1132-1136 Nov. 15, 1998
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

10576179 BIOSIS NO.: 199699197324
Linomide prevents the lethal effect of anti-fas **antibody** and reduces
Fas-mediated ceramide production in mouse hepatocytes.

AUTHOR: Redondo Clara; Flores Ignacio; Gonzalez Ana; Nagata Shigekazu;
Carrera Ana C; Merida Isabel; Martinez-A Carlos(a)
AUTHOR ADDRESS: (a) Centro Nacional de Biotecnologia, Universidad Autonoma,
Campus de Cantoblanco, 28049 Madrid, Spain

JOURNAL: Journal of Clinical Investigation 98 (5):p1245-1252 1996
ISSN: 0021-9738
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1999 BIOSIS. All rts. reserv.

10292127 BIOSIS NO.: 199698747045

Effect of the conjugate composed of a human monoclonal **antibody** and
pingyangmycin on mammary cancer.

AUTHOR: Wang W G(a); Wang S H; Xue Y C(a); Zhen Y S(a)

AUTHOR ADDRESS: (a)Inst. Med. Biotechnol., Chinese Acad. Med. Sci., Peking
Union Med. Coll., Beijing 100050, China

JOURNAL: Yaoxue Xuebao 30 (8):p583-587 1995

ISSN: 0513-4870

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: Chinese; Non-English

SUMMARY LANGUAGE: Chinese; English

4/3/4 (Item 4 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1999 BIOSIS. All rts. reserv.

10140779 BIOSIS NO.: 199698595697

Distribution of all-trans retinoic acid in normal and vitamin A deficient
mice: Correlation to retinoic acid receptors in different tissues of
normal mice.

AUTHOR: Zhuang Ya-Hua(a); Sainio Eeva-Liisa; Sainio Pertti; Vedeckis Wayne
V; Ylikomi Timo; Tuohimaa Pentti

AUTHOR ADDRESS: (a)Dep. Anat., Med. Sch., Univ. Tampere, 33101 Tampere,
Finland

JOURNAL: General and Comparative Endocrinology 100 (2):p170-178 1995

ISSN: 0016-6480

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/5 (Item 5 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1999 BIOSIS. All rts. reserv.

10002761 BIOSIS NO.: 199598457679

Relative bioavailability of cyclosporin from conventional and microemulsion
formulations in **heart-lung** transplant candidates with cystic
fibrosis.

AUTHOR: Tan K K C(a); Trull A K; Uttridge J A; Wallwork J

AUTHOR ADDRESS: (a)Pfizer Cent. Res., Ramsgate Rd., Sandwich, Kent CT13 9NJ
, UK

JOURNAL: European Journal of Clinical Pharmacology 48 (3-4):p285-289 1995

ISSN: 0031-6970

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/6 (Item 6 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1999 BIOSIS. All rts. reserv.

09025574 BIOSIS NO.: 199497033944

Experimental studies on therapeutic effect of rat monoclonal **antibody**

-bleomycin A6 conjugate against human colorectal cancer.

AUTHOR: Deng Y C; Zhen Y S; Zheng S; Jiang M
AUTHOR ADDRESS: Inst. Med. Biotechnol., Chinese Acad. Med. Sci., Beijing
100050, China

JOURNAL: Acta Pharmaceutica Sinica 28 (6):p410-415 1993
ISSN: 0513-4870
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Chinese; Non-English
SUMMARY LANGUAGE: Chinese; English

4/3/7 (Item 7 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

08969111 BIOSIS NO.: 199396120612
What factors determine indium-111 antimyosin monoclonal **antibody**
uptake in patients with myocardial infarction?

AUTHOR: Ouzan J(a); Metz D; Jolly D; Liehn J C; Elaerts J
AUTHOR ADDRESS: (a)4 Rue Chanzy, 51100 Reims, France

JOURNAL: International Journal of Cardiology 40 (3):p257-263 1993
ISSN: 0167-5273
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 8 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

08958024 BIOSIS NO.: 199396109525
Lethal effect of the anti-fas **antibody** in mice.

AUTHOR: Ogasawara Jun; Watanabe-Fukunaga Rie; Adachi Masashi; Matsuzawa
Akio; Kasugai Tsutomu; Kitamura Yukihiro; Itoh Naoto; Suda Takashi;
Nagata Shigekazu(a)
AUTHOR ADDRESS: (a)Osaka Bioscience Inst., 6-2-4 Furuedai, Suita, Osaka 565
, Japan

JOURNAL: Nature (London) 364 (6440):p806-809 1993
ISSN: 0028-0836
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/9 (Item 9 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

08913420 BIOSIS NO.: 199396064921
Tumor necrosis factor is a mediator of phospholipase release during
bacteremia in baboons.

AUTHOR: Redl H(a); Schlag G; Schiessner A; Davies J
AUTHOR ADDRESS: (a)Ludwig Boltzmann Inst. Experimental Clinical Traumatol.,
Donaueschingenstr. 13, A-1200 Vienna, Austria

JOURNAL: American Journal of Physiology 264 (6 PART 2):pH2119-H2123 1993

ISSN: 0002-9513
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/10 (Item 10 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

08860322 BIOSIS NO.: 199396011823
Cardiotoxicity of human recombinant interleukin-2 in rats: A morphological study.

AUTHOR: Zhang Jun; Yu Zu-Xi; Hilbert Stephen L; Yamaguchi Maria; Chadwick Douglas P; Herman Eugene H; Ferrans Victor J(a)
AUTHOR ADDRESS: (a)Build. 10, Room 2N240, NIH, Bethesda, MD 20892, USA

JOURNAL: Circulation 87 (4):p1340-1353 1993
ISSN: 0009-7322
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1999 BIOSIS. All rts. reserv.

08727640 BIOSIS NO.: 199395016991
Monoclonal **antibody** to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys.

AUTHOR: Fiedler Volker B(a); Loff Ingo; Sander Erich; Voehringer Verena;
Galanos Chris; Fournel Michael A
AUTHOR ADDRESS: (a)Lehmer Muehle 46, D-5090 Leverkusen 3, Germany

JOURNAL: Journal of Laboratory and Clinical Medicine 120 (4):p574-588 1992
ISSN: 0022-2143
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/12 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07549292 EMBASE No: 1999041324
Chlamydia pneumoniae infection associated with multi-organ failure and fatal outcome in a previously healthy patient
Gnarpe J.; Gnarpe H.; Nissen K.; Haldar K.; Naas J.
Dr. J. Gnarpe, Department of Clinical Microbiology, Gavle Central Hospital, S-801 87 Gavle Sweden
Scandinavian Journal of Infectious Diseases (SCAND. J. INFECT. DIS.) (Norway) 1998, 30/5 (523-524)

CODEN: SJIDB ISSN: 0036-5548
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 17

4/3/13 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

07447435 EMBASE No: 1998360469

Gastric perforation due to mucormycosis after **heart-lung** and heart transplantation

Knoop C.; Antoine M.; Vachieri J.L.; Depre G.; Alonso-Vega C.; Struelens M.; Van Laethem J.L.; Lingier P.; Nagy N.; Jacobs F.; Kramer M.R.; Estenne M.

C. Knoop, Department of Chest Medicine, Erasme University Hospital, 808, Route de Lennik, 1070 Brussels Belgium
Transplantation (TRANSPLANTATION) (United States) 15 OCT 1998, 66/7 (932-935)

CODEN: TRPLA ISSN: 0041-1337

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 10

4/3/14 (Item 3 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

07392546 EMBASE No: 1998307950

Influence of various combinations of specific **antibody dose** and affinity on tissue imipramine redistribution

Ragusi C.; Boschi G.; Risede P.; Rips R.; Harrison K.; Scherrmann J.-M.
C. Ragusi, INSERM U26, Hopital Fernand Widal, 200 rue du Faubourg Saint Denis, F75475 Paris cedex 10 France
British Journal of Pharmacology (BR. J. PHARMACOL.) (United Kingdom) 1998, 125/1 (35-40)

CODEN: BJPCB ISSN: 0007-1188

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 22

4/3/15 (Item 4 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

07242260 EMBASE No: 1998093310

Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy

Mourad G.; Vela C.; Ribstein J.; Mimran A.
Dr. G. Mourad, Department of Nephrology, Hopital Lapeyronie, 34295 Montpellier Cedex 5 France
Transplantation (TRANSPLANTATION) (United States) 15 MAR 1998, 65/5 (661-667)

CODEN: TRPLA ISSN: 0041-1337

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 37

4/3/16 (Item 5 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

07140684 EMBASE No: 1998029625

Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity

Maini C.L.; Sciuto R.; Ferraironi A.; Vici P.; Tofani A.; Festa A.; Conti F.; Lopez M.

Dr. C.L. Maini, La Pietra Pizzuta, 03010 Patrica (FR) Italy

Journal of Nuclear Cardiology (J. NUCL. CARDIOL.) (United States) 1997
, 4/6 (502-508)

CODEN: JNCAE ISSN: 1071-3581

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 33

4/3/17 (Item 6 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

07007309 EMBASE No: 1997293785

Receptor mediated delivery of daunomycin using immunoliposomes:
Pharmacokinetics and tissue distribution in the rat

Huwyler J.; Yang J.; Pardridge W.M.

Dr. W.M. Pardridge, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095-1682 United States

Journal of Pharmacology and Experimental Therapeutics (J. PHARMACOL.

EXP. THER.) (United States) 1997, 282/3 (1541-1546)

CODEN: JPETA ISSN: 0022-3565

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 32

4/3/18 (Item 7 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

06977301 EMBASE No: 1997261988

Acute graft-versus-host disease after human heart-lung
transplantation: A case report

Pfitzmann R.; Hummel M.; Grauhan O.; Waurick P.; Ewert R.; Loebe M.; Weng Y.; Hetzer R.

Dr. R. Pfitzmann, Deutsches Herzzentrum Berlin, Cardiac

Surgery/Transplant Division, Augustenburger Platz 1, 13353 Berlin

Germany

Journal of Thoracic and Cardiovascular Surgery (J. THORAC. CARDIOVASC.

SURG.) (United States) 1997, 114/2 (285-287)

CODEN: JTCSA ISSN: 0022-5223

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 5

4/3/19 (Item 8 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

06928933 EMBASE No: 1997213412

Perioperative anaesthetic considerations for patients undergoing lung
transplantation

Singh H.; Bossard R.F.

Dr. H. Singh, Dept. of Anesthesiology/Pain Mgmt., Texas Univ.

Southwestern Med. Ctr., 5323 Harry Hines Blvd, Dallas, TX 75235-9068

United States

Canadian Journal of Anaesthesia (CAN. J. ANAESTH.) (Canada) 1997, 44/3
(284-299)

CODEN: CJOAE ISSN: 0832-610X
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH; FRENCH
NUMBER OF REFERENCES: 100

4/3/20 (Item 9 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06870168 EMBASE No: 1997154496
Bronchiolitis obliterans syndrome in **heart-lung**
transplantation: Surveillance biopsies
Tamm M.; Sharples L.D.; Higenbottam T.W.; Stewart S.; Wallwork J.
Dr. L.D. Sharples, Research and Development Unit, Papworth Hospital NHS
Trust, Papworth Everard, Cambridge CB3 8RE United Kingdom
American Journal of Respiratory and Critical Care Medicine (AM. J.
RESPIR. CRIT. CARE MED.) (United States) 1997, 155/5 (1705-1710)

CODEN: AJCME ISSN: 1073-449X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 32

4/3/21 (Item 10 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06804572 EMBASE No: 1997087057
Tacrolimus (FK506) proves superior to OKT3 for treating episodes of
persistent rejection following intrathoracic transplantation
Meiser B.M.; Uberfuhr P.; Schulze C.; Fuchs A.; Mair H.; Reichenspurner
H.; Kreuzer E.; Reichart B.
Dr. B.M. Meiser, Klinikum Grosshadern, Herzchirurgische Poliklinik,
Ludwig-Maximilians Univ. Munchen, Marchioninstrasse 15, 81377 Munchen
Germany
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 1997,
29/1-2 (605-606)

CODEN: TRPPA ISSN: 0041-1345
PUBLISHER ITEM IDENTIFIER: S0041134596003211
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 9

4/3/22 (Item 11 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06711152 EMBASE No: 1996376108
Defining an optimal regimen for cytomegalovirus prophylaxis in organ
transplant recipients
Paya C.V.
Mayo Clinic, Rochester, MN 55905 United States
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 1996,
28/6 SUPPL. 2 (9-11)

CODEN: TRPPA ISSN: 0041-1345
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH

4/3/23 (Item 12 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06704566 EMBASE No: 1996369515
Pharmacodynamics of cyclosporine in heart and **heart-lung**
transplant recipients: I: Blood cyclosporine concentrations and other risk
factors for cardiac allograft rejection
Best N.G.; Trull A.K.; Tan K.K.C.; Spiegelhalter D.J.; Cary N.; Wallwork
J.
Dept. of Epidemiology/Public Health, Imperial College School of Medicine,
Norfolk Place, London W2 1PG United Kingdom
Transplantation (TRANSPLANTATION) (United States) 1996, 62/10
(1429-1435)

CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/24 (Item 13 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06608911 EMBASE No: 1996273684
Consequences of hypogammaglobulinemia and steroid therapy in severe
bronchopulmonary dysplasia
Wheeler W.; Kurachek S.; McNamara J.; Fugate J.; Hoogenhous N.
2545 Chicago Avenue South, Minneapolis, MN 55404 United States
Pediatric Pulmonology (PEDIATR. PULMONOL.) (United States) 1996, 22/2
(96-100)

CODEN: PEPUE ISSN: 8755-6863
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/25 (Item 14 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06543539 EMBASE No: 1996203211
Impaired endothelium-mediated vasodilatation in the peripheral
vasculature of patients with acute pulmonary allograft rejection
Schersten H.; Kirno K.; Ekroth R.; Lundin S.; Pettersson A.; Kjellstrom
C.; Miller V.M.; Nilsson F.
Division of Cardiothoracic Surgery, Sahlgrenska University Hospital, S-413
45 Goteborg Sweden
Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1996, 15/6 (556-563)

CODEN: JHLTE ISSN: 1053-2498
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/26 (Item 15 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06523291 EMBASE No: 1996167391
Heart-lung transplantation for cystic fibrosis
TRANSPLANTATION CARDIOPULMONAIRE ET MUCOVISCIDOSE. INDICATIONS ET
RESULTATS
Haloun A.; Despins P.; Horeau D.; Thrielhaud M.; Portier D.; De Lajartre

A.Y.; Jegou B.; Al Habach O.; Train M.; Duveau D.; Caillon J.; Michaud J.L.
Unite de Transplantation Thoracique, Hopital Laennec, CHU, 44035 Nantes
Cedex 01 France
Archives de Pediatrie (ARCH. PEDIATR.) (France) 1996, 3/5 (427-432)

CODEN: APEDE ISSN: 0929-693X
DOCUMENT TYPE: Journal; Article
LANGUAGE: FRENCH SUMMARY LANGUAGE: FRENCH; ENGLISH

4/3/27 (Item 16 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06513857 EMBASE No: 1996169975
Synergistic induction of metallothionein synthesis by interleukin-6,
dexamethasone and zinc in the rat
Sato M.; Yamaki J.; Hamaya M.; Hojo H.
Department of Biomolecular Sciences, Institute of Biomedical Sciences,
Fukushima Medical College, 1 Hikarigaoka, Fukushima 960-12 Japan
International Journal of Immunopharmacology (INT. J. IMMUNOPHARMACOL.)
(United Kingdom) 1996, 18/2 (167-172)

CODEN: IJIMD ISSN: 0192-0561
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/28 (Item 17 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06511617 EMBASE No: 1996176949
Heart-lung-liver transplantation
Dennis C.M.; McNeil K.D.; Dunning J.; Stewart S.; Friend P.J.; Alexander
G.; Higenbottam T.W.; Calne R.Y.; Wallwork J.
Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD 4032
Australia
Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1996, 15/5 (536-538)

CODEN: JHLTE ISSN: 1053-2498
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/29 (Item 18 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06480444 EMBASE No: 1996126626
Pulmonary allograft ischemic time: An important predictor of survival
after lung transplantation
Snell G.I.; Rabinov M.; Griffiths A.; Williams T.; Ugoni A.; Salamonsson
R.; Esmore D.
Heart and Lung Replacement Service, Alfred Hospital, Prahran, Vic. 3181
Australia
Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1996, 15/2 (160-168)

CODEN: JHLTE ISSN: 1053-2498
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/30 (Item 19 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06462878 EMBASE No: 1996129034
Surgical management of pulmonary hypertension
Kriett J.M.; Jamieson S.W.
Division of Cardiothoracic Surgery, UCSD Medical Center 8892, 200 West
Arbor Drive, San Diego, CA 92103 United States
Seminars in Respiratory and Critical Care Medicine (SEMIN. RESPIR. CRIT.
CARE MED.) (United States) 1996, 17/2 (149-158)

CODEN: SRCCE ISSN: 1069-3424
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH

4/3/31 (Item 20 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06451791 EMBASE No: 1996116794
Total lymphoid irradiation for resistant rejection after heart
transplantation: Only moderate success medium-term
Keogh A.; Morgan G.; Macdonald P.; Spratt P.; Mundy J.; McCosker C.
Heart and Lung Transplant Unit, St. Vincent's Hospital, Victoria
Street, Darlinghurst, NSW 2010 Australia
Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (
United States) 1996, 15/3 (231-233)

CODEN: JHLTE ISSN: 1053-2498
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/32 (Item 21 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06419296 EMBASE No: 1996077539
Obliterative bronchiolitis after lung and **heart-lung**
transplantation
Reichenspurner H.; Girgis R.E.; Robbins R.C.; Conte J.V.; Nair R.V.;
Valentine V.; Berry G.J.; Morris R.E.; Theodore J.; Reitz B.A.
Dept. of Cardiothoracic Surgery, Stanford University, Medical
Center, Stanford, CA 94305-5247 United States
Annals of Thoracic Surgery (ANN. THORAC. SURG.) (United States) 1995,
60/6 (1845-1853)

CODEN: ATHSA ISSN: 0003-4975
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/33 (Item 22 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06414621 EMBASE No: 1996075348
Development of bronchiolitis obliterans syndrome in recipients of
heart- lung transplantation - Early risk factors
Sharples L.D.; Tamm M.; McNeil K.; Higenbottam T.W.; Stewart S.; Wallwork
J.
Department of Research/Development, Papworth Hospital, Papworth
Everard, Cambridge CB3 8RE United Kingdom

Transplantation (TRANSPLANTATION) (United States) 1996, 61/4 (560-566)

CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/34 (Item 23 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06408989 EMBASE No: 1996072746
Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome
following lung transplantation
Kesten S.; Rajagopalan N.; Maurer J.
10 Norman Urquhart, Toronto Hospital, 200 Elizabeth Street, Toronto, Ont.
M5G 2C4 Canada
Transplantation (TRANSPLANTATION) (United States) 1996, 61/3 (427-430)

CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/35 (Item 24 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06350011 EMBASE No: 1996013546
Cytomegalovirus infection in organ transplant recipients
Hibberd P.L.; Sydnman D.R.
Infectious Disease Unit, Massachusetts General Hospital, 32 Fruit
Street, Boston, MA 02114 United States
Infectious Disease Clinics of North America (INFECT. DIS. CLIN. NORTH
AM.) (United States) 1995, 9/4 (863-877)

CODEN: IDCAE ISSN: 0891-5520
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/36 (Item 25 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06323372 EMBASE No: 1995357991
Overlapping syndromes, undifferentiated connective tissue disease, and
other fibrosing conditions
Kallenberg C.G.M.
Department of Clinical Immunology, University Hospital Groningen,
Oostersingel 59, 9713 EZ Groningen Netherlands
Current Opinion in Rheumatology (CURR. OPIN. RHEUMATOL.) (United States
) 1995, 7/6 (568-573)

CODEN: CORHE ISSN: 1040-8711
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/37 (Item 26 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06294368 EMBASE No: 1995332487
Prevention and treatment of cytomegalovirus disease in thoracic organ

transplant patients: Evidence for a beneficial effect of hyperimmune globulin

Valantine H.A.

Falk Cardiovascular Research Center, Stanford University Sch. of Medicine, 3000 Pasteur Drive, Stanford, CA 94305-5346 United States
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 1995, 27/5 SUPPL. 1 (49-57)

CODEN: TRPPA ISSN: 0041-1345
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH

4/3/38 (Item 27 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06268458 EMBASE No: 1995305137

The incidence of renal failure in one hundred consecutive **heart-lung** transplant recipients

Pattison J.M.; Petersen J.; Kuo P.; Valantine V.; Robbins R.C.; Theodore J.

Division of Nephrology, Stanford University Medical Center, Stanford, CA 94305-5114 United States
American Journal of Kidney Diseases (AM. J. KIDNEY DIS.) (United States) 1995, 26/4 (643-648)

CODEN: AJKDD ISSN: 0272-6386
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/39 (Item 28 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06237887 EMBASE No: 1995256702

Effect of vitamin E supplementation on immune status and alpha-tocopherol in plasma of piglets

Hidiroglou M.; Batra T.R.; Farnworth E.R.; Markham F.

Centre for Food and Animal Research, Agricultural and Agri-Food Canada, Ottawa, Ont. K1A 0C6 Canada

Reproduction Nutrition Development (REPROD. NUTR. DEV.) (France) 1995, 35/4 (443-450)

CODEN: RNDEE ISSN: 0926-5287
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH; FRENCH

4/3/40 (Item 29 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06235731 EMBASE No: 1995270789

Glomerular disease and lung transplantation

Paller M.S.; Cahill B.; Harmon K.R.; Miller R.B.; Sinaiko A.R.; Burke B.; Manivel J.C.

University of Minnesota, Box 736 UMHC, 420 Delaware St SE, Minneapolis, MN 55455 United States

American Journal of Kidney Diseases (AM. J. KIDNEY DIS.) (United States) 1995, 26/3 (527-531)

CODEN: AJKDD ISSN: 0272-6386
DOCUMENT TYPE: Journal; Article

4/3/41 (Item 30 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06208916 EMBASE No: 1995241709
Relative bioavailability of cyclosporin from conventional aid
microemulsion formulations in **heart-lung** transplant candidates
with cystic fibrosis
Tan K.K.C.; Trull A.K.; Uttridge J.A.; Wallwork J.
Clinical/Biochemical Pharmacol. Unit, Papworth Hospital, Cambridge United
Kingdom
European Journal of Clinical Pharmacology (EUR. J. CLIN. PHARMACOL.) (Germany) 1995, 48/3-4 (285-289)

CODEN: EJCPA ISSN: 0031-6970
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/42 (Item 31 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06187896 EMBASE No: 1995210323
Percutaneous cardiopulmonary bypass for cardiogenic shock caused by
poisoning with metildigoxin, nifedipine and indapamide
PERKUTANE EXTRAKORPORALE ZURKULATION BEI KARDIOGENEM SCHOCK AUFGRUND
EINER MISCHINTOXIKATION MIT METILDIGOXIN, NIFEDIPIN UND INDAPAMID
Schmidt W.; Reissig M.; Neuhaus K.-L.
Medizinische Klinik II, Stadtische Kliniken, Monchebergstrasse
41-43, 34125 Kassel Germany
Deutsche Medizinische Wochenschrift (DTSCH. MED. WOCHENSCHR.) (Germany)
1995, 120/28-29 (996-1002)

CODEN: DMWOA ISSN: 0012-0472
DOCUMENT TYPE: Journal; Article
LANGUAGE: GERMAN SUMMARY LANGUAGE: GERMAN; ENGLISH

4/3/43 (Item 32 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06097087 EMBASE No: 1995127687
Cancers following thoracic organ transplantation: A single center study
Burtin P.; Boman F.; Pinelli G.; Mattei M.F.; Dopff C.; Villemot J.P.
Departement d'Anesthesie, CHU de Brabois, Rue du Morvan, 54511
Vandoeuvre-les-Nancy France
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 1995,
27/2 (1765-1766)

CODEN: TRPPA ISSN: 0041-1345
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH

4/3/44 (Item 33 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06079148 EMBASE No: 1995109632
Direct gene delivery of human tissue kallikrein reduces blood pressure in

spontaneously hypertensive rats

Wang C.; Chao L.; Chao J.

Biochemistry/Molecular Biol. Dept., Medical University of South

Carolina, Charleston, SC 29425-2211 United States

Journal of Clinical Investigation (J. CLIN. INVEST.) (United States)

1995, 95/4 (1710-1716)

CODEN: JCINA ISSN: 0021-9738

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/45 (Item 34 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

06030170 EMBASE No: 1995060359

Improved results of lung transplantation for patients with cystic fibrosis

Egan T.M.; Detterbeck F.C.; Mill M.R.; Paradowski L.J.; Lackner R.P.; Ogden W.D.; Yankaskas J.R.; Westerman J.H.; Thompson J.T.; Weiner M.A.; Cairns E.L.; Wilcox B.R.; Patterson A.; Benfield J.R.; Rahman A.; Starnes V.A.

108 Burnett-Womack Building, CB 7065, Chapel Hill, NC 27599-7065 United States

Journal of Thoracic and Cardiovascular Surgery (J. THORAC. CARDIOVASC. SURG.) (United States) 1995, 109/2 (224-235)

CODEN: JTCSA ISSN: 0022-5223

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/46 (Item 35 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

06002882 EMBASE No: 1995031534

Critical issues in pediatric lung transplantation

Armitage J.M.; Kurland G.; Michaels M.; Cipriani L.A.; Griffith B.P.; Fricker F.J.; Trinkle J.K.; Egan T.M.; Haverich A.; Starnes V.A.

C700 PUH-UPMC, Pittsburgh University Medical Center, 200 Lothrop St., Pittsburgh, PA 15213 United States

Journal of Thoracic and Cardiovascular Surgery (J. THORAC. CARDIOVASC. SURG.) (United States) 1995, 109/1 (60-65)

CODEN: JTCSA ISSN: 0022-5223

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/47 (Item 36 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

05975932 EMBASE No: 1995003101

FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: Report on five cases

Knoop C.; Antoine M.; Vachiery J.L.; Yernault J.C.; Estenne M. Chest Service, Erasme Hospital, 808, Route de Lennik, B-1070 Brussels Belgium

Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 1994, 26/6 (3240-3241)

CODEN: TRPPA ISSN: 0041-1345

DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH

4/3/48 (Item 37 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05962321 EMBASE No: 1994371306
Heart-lung and lung transplantation in pulmonary hypertension
Butt A.Y.; Higenbottam T.W.
Regional Pulmonary Physiology Lab., Papworth Everard, Papworth
Hospital, Cambridge CB3 8RF United Kingdom
Seminars in Respiratory and Critical Care Medicine (SEMIN. RESPIR. CRIT.
CARE MED.) (United States) 1994, 15/6 (508-515)

CODEN: SRCCE ISSN: 1069-3424
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH

4/3/49 (Item 38 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05955737 EMBASE No: 1994372834
Long-term results of combined **heart-lung** transplantation: The
Stanford experience
Sarris G.E.; Smith J.A.; Shumway N.E.; Stinson E.B.; Oyer P.E.; Robbins
R.C.; Billingham M.E.; Theodore J.; Moore K.A.; Reitz B.A.
Onassis Cardiac Surgery Center, 356 Sygrov Ave., Athens 17674 Greece
Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1994, 13/6 (940-949)

CODEN: JHLTE ISSN: 1053-2498
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/50 (Item 39 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05955345 EMBASE No: 1994374940
Outcome of Toxoplasma gondii mismatches in heart transplant recipients
over a period of 8 years
Orr K.E.; Gould F.K.; Short G.; Dark J.H.; Hilton C.J.; Corris P.A.;
Freeman R.
Department of Microbiology, Freeman Hospital, Newcastle upon Tyne NE7 7DN
United Kingdom
Journal of Infection (J. INFECT.) (United Kingdom) 1994, 29/3
(249-253)

CODEN: JINFD ISSN: 0163-4453
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/51 (Item 40 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05946799 EMBASE No: 1994357495
Pseudomonas aeruginosa aortic aneurysm after **heart-lung**
transplantation for cystic fibrosis

Cassart M.; Gevenois P.-A.; Knoop C.; Antoine M.; Vachiere J.-L.; Leclerc
- J.L.; Struelens M.; Nonhoff C.; Jacobs F.; Serruys E.; Baran D.; Yernault
- J.C.; Estenne M.

Department of Radiology, Erasme University Hospital, 808 route de
Lennik, B-1070 Brussels Belgium
Transplantation (TRANSPLANTATION) (United States) 1994, 58/9
(1051-1053)

CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH

4/3/52 (Item 41 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05867982 EMBASE No: 1994284888
Effect of interleukin-2 on the biodistribution of technetium-99m-labelled
anti-CEA monoclonal **antibody** in mice bearing human tumour xenografts

Nakamura K.; Kubo A.
Department of Radiology, School of Medicine, Keio University, 35
Shinanomachi, Shinjuku-ku, Tokyo 160 Japan
European Journal of Nuclear Medicine (EUR. J. NUCL. MED.) (Germany)
1994, 21/9 (924-929)

CODEN: EJNMD ISSN: 0340-6997
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/53 (Item 42 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05831762 EMBASE No: 1994237879
Heart, **heart-lung** and lung transplantation
HERZ-, HERZ-LUNGEN- UND LUNGENTRANSPLANTATION, STAND 1994
Reichenspurner H.; Uberfuhr P.; Dienemann H.; Reichart B.
Herzchirurgische Universitätsklinik, Klinikum Grosshadern,
Marchioninistrasse 15, D-81366 Munchen Germany
Fortschritte der Medizin (FORTSCHR. MED.) (Germany) 1994, 112/20-21
(27-32)

CODEN: FMDZA ISSN: 0015-8178
DOCUMENT TYPE: Journal; Short Survey
LANGUAGE: GERMAN SUMMARY LANGUAGE: GERMAN; ENGLISH

4/3/54 (Item 43 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05816037 EMBASE No: 1994228989
Double lung transplantation in situs inversus with Kartagener's syndrome
Macchiarini P.; Chapelier A.; Vouhe P.; Cerrina J.; Ladurie F.L.R.;
Parquin F.; Brenot F.; Simonneau G.; Dartevelle P.
DTVSHLT, Hopital Marie-Lannelongue, Paris-Sud University, 133, Avenue de
la Resistance, 92350 Plessis Robinson France
Journal of Thoracic and Cardiovascular Surgery (J. THORAC. CARDIOVASC.
SURG.) (United States) 1994, 108/1 (86-91)

CODEN: JTCSA ISSN: 0022-5223
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/55 (Item 44 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05815404 EMBASE No: 1994232519
Clinical characteristics of post-transplant lymphoproliferative disorders
Morrison V.A.; Dunn D.L.; Manivel J.C.; Gajl-Peczalska K.J.; Peterson
B.A.
Section of Hematology/Oncology, Veterans Affairs Medical Center, 1
Veterans Drive, Minneapolis, MN 55417 United States
American Journal of Medicine (AM. J. MED.) (United States) 1994, 97/1
(14-24)

CODEN: AJMEA ISSN: 0002-9343
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/56 (Item 45 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05814970 EMBASE No: 1994198744
Differential induction of nitric oxide synthase in various organs of the
mouse during endotoxaemia: Role of TNF-alpha and IL-1-beta
Cunha F.Q.; Assreuy J.; Moss D.W.; Rees D.; Leal L.M.C.; Moncada S.;
Carrier M.; O'Donnell C.A.; Liew F.Y.
Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS
United Kingdom
Immunology (IMMUNOLOGY) (United Kingdom) 1994, 81/2 (211-215)

CODEN: IMMUA ISSN: 0019-2805
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/57 (Item 46 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05767012 EMBASE No: 1994172897
Complications of pediatric lung and **heart-lung**
transplantation
Kurland G.; Orenstein D.M.
Division of Pediatric Pulmonology, Department of Pediatrics, Children's
Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213 United
States
Current Opinion in Pediatrics (CURR. OPIN. PEDIATR.) (United States)
1994, 6/3 (262-271)

CODEN: COPEE ISSN: 1040-8703
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/58 (Item 47 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05734591 EMBASE No: 1994132015
Heart-lung, single and double lung transplantation
Kendall S.W.H.; Ciulli F.C.; Dennis C.M.J.; Mullins P.A.; Parameshwar J.;
McGoldrick J.P.; Large S.R.; Wells F.C.; Wallwork J.

Transplant Unit, Papworth Hospital, Papworth Everard, Cambridge CB3 8RE
United Kingdom
Acta Chirurgica Austriaca (ACTA CHIR. AUSTRIACA) (Austria) 1994, 26/1
(13-18)

CODEN: ACAUB ISSN: 0001-544X
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH; GERMAN

4/3/59 (Item 48 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05700636 EMBASE No: 1994108741
Isolated lung transplantation: Results of 17 consecutive operations
ISOLIERTE LUNGENTRANSPLANTATION. ANALYSE VON 17 KONSEKUTIVEN OPERATIONEN
Dienemann H.; Reichenspurner H.; Forst H.; Reichart B.
Chirurgische Klinik und Poliklinik, Klinikum Grosshadern, Universitat
Munchen, Marchioninistrasse 15, 81366 Munchen Germany
Deutsche Medizinische Wochenschrift (DTSCH. MED. WOCHENSCHR.) (Germany)
1994, 119/13 (451-457)

CODEN: DMWOA ISSN: 0012-0472
DOCUMENT TYPE: Journal; Article
LANGUAGE: GERMAN SUMMARY LANGUAGE: GERMAN; ENGLISH

4/3/60 (Item 49 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05699891 EMBASE No: 1994109606
Physiologically based pharmacokinetic model for specific and nonspecific
monoclonal **antibodies** and fragments in normal tissues and human tumor
xenografts in nude mice
Baxter L.T.; Zhu H.; Mackensen D.G.; Jain R.K.
Department of Radiation Oncology, Harvard Medical School, Massachusetts
General Hospital, Boston, MA 02114 United States
Cancer Research (CANCER RES.) (United States) 1994, 54/6 (1517-1528)

CODEN: CNREA ISSN: 0008-5472
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/61 (Item 50 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05698926 EMBASE No: 1994116502
Chronic rejection- Definition and correlates
Matas A.J.
Department of Surgery, University of Minnesota, Minneapolis, MN United
States
Clinical Transplantation (CLIN. TRANSPLANT.) (Denmark) 1994, 8/2 II
(162-167)

CODEN: CLTRE ISSN: 0902-0063
DOCUMENT TYPE: Journal; Short Survey
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/62 (Item 51 from file: 72)
DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

05614138 EMBASE No: 1994013648

Incidence and treatment of neoplasia after transplantation

Penn I.

Department of Surgery, Cincinnati University Medical Center, 231 Bethesda Ave., Cincinnati, OH 45267-0558 United States

Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1993, 12/6 II (S328-S336)

CODEN: JHLTE ISSN: 1053-2498

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/63 (Item 52 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

05614136 EMBASE No: 1994013646

Graft coronary disease in pediatric heart and combined **heart-lung** transplant recipients: A study of fifteen cases

Berry G.J.; Rizeq M.N.; Weiss L.M.; Billingham M.E.

Department of Pathology, Stanford University Medical Center, Stanford, CA 94305 United States

Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1993, 12/6 II (S309-S319)

CODEN: JHLTE ISSN: 1053-2498

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/64 (Item 53 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

05612468 EMBASE No: 1994013592

Incidence of obliterative bronchiolitis after **heart-lung** transplantation in children

Whitehead B.; Rees P.; Sorensen K.; Bull C.; Higenbottam T.W.; Wallwork J.; Fabre J.; Elliott M.; De Leval M.

Hospital for Sick Children, Great Ormond Street, London WC1N 3JH United Kingdom

Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1993, 12/6 I (903-908)

CODEN: JHLTE ISSN: 1053-2498

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/65 (Item 54 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1999 Elsevier Science B.V. All rts. reserv.

05529853 EMBASE No: 1993297952

Single-lung retransplantation for late graft failure

Fournier M.; Sleiman C.; Mal H.; Groussard O.; Mollo J.-L.; Duchatelle J.-P.; Andreassian B.; Pariente R.

Serv. de Pneumologie et Reanimation, Hopital Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy Cedex France

European Respiratory Journal (EUR. RESPIR. J.) (Denmark) 1993, 6/8 (1202-1206)

CODEN: ERJOE ISSN: 0903-1936
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/66 (Item 55 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05502301 EMBASE No: 1993270400
A decade of lung transplantation
Griffith B.P.; Hardesty R.L.; Armitage J.M.; Hattler B.G.; Pham S.M.;
Keenan R.J.; Paradis I.; Shumway N.E.; Benfield J.R.; Mulder D.S.; Ginsberg
R.J.
Division of Cardiothoracic Surgery, University of Pittsburgh,
Presbyterian University Hospital, DeSoto at O'Hara Streets, Pittsburgh, PA
15213 United States
Annals of Surgery (ANN. SURG.) (United States) 1993, 218/3 (310-320)

CODEN: ANSUA ISSN: 0003-4932
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/67 (Item 56 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05453245 EMBASE No: 1993221344
The medical management of patients with cystic fibrosis following
heart-lung transplantation
Madden B.P.; Kamalvand K.; Chan C.M.; Khaghani A.; Hodson M.E.; Yacoub M.
Dept. of Cystic Fibrosis, Royal Brompton Nat. Heart/Lung Hosp., Sydney
Street, London SW3 6NP United Kingdom
European Respiratory Journal (EUR. RESPIR. J.) (Denmark) 1993, 6/7
(965-970)

CODEN: ERJOE ISSN: 0903-1936
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/68 (Item 57 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05415156 EMBASE No: 1993183255
Immunosuppressive therapy as a determinant of transplantation outcomes
Evans R.W.; Manninen D.L.; Dong F.B.; Ascher N.L.; Frist W.H.; Hansen
J.A.; Kirklin J.K.; Perkins J.D.; Pirsch J.D.; Sanfilippo F.P.
Dept. of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
United States
Transplantation (TRANSPLANTATION) (United States) 1993, 55/6
(1297-1305)

CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/69 (Item 58 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05377537 EMBASE No: 1993145636

Management of lung transplant rejection
Trulock E.P.
Pulmonary and Critical Care Medicine, Box 8052, 660 South Euclid, St.
Louis, MO 63110 United States
Chest (CHEST) (United States) 1993, 103/5 (1566-1576)

CODEN: CHETB ISSN: 0012-3692
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/70 (Item 59 from file: 72)
DIALOG(R) File 72: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05331766 EMBASE No: 1993099851
Antibody formation after drug **administration** during cardiac
surgery: Parameters for aprotinin use
Levy J.H.
The Emory Clinic, 1365 Clifton Road NE, Atlanta, GA 30322 United States
Journal of Heart and Lung Transplantation (J. HEART LUNG TRANSPLANT.) (United States) 1993, 12/1 I (S26-S33)

CODEN: JHLTE ISSN: 1053-2498
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/71 (Item 60 from file: 72)
DIALOG(R) File 72: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05329942 EMBASE No: 1993098027
Cellular mechanisms underlying differential rejection of sequential heart
and lung allografts in rats
Moller F.; Hoyt G.; Farfan F.; Starnes V.A.; Clayberger C.
Department of Cardiothoracic Surgery, Stanford Univ. School of
Medicine, Stanford, CA 94305 United States
Transplantation (TRANSPLANTATION) (United States) 1993, 55/3 (650-655)

CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/72 (Item 61 from file: 72)
DIALOG(R) File 72: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05297211 EMBASE No: 1993065296
Cytomegalovirus-specific cell-mediated immune responses in heart and
heart-lung transplant recipients are not predictive for the
occurrence of symptomatic CMV disease or tissue rejection
Van Tiel F.H.; Rasmussen L.; Merigan T.C.
Medische Microbiologie, Academisch Ziekenhuis Maastricht, Postbus
5800, 6202 AZ Maastricht Netherlands
Journal of Interferon Research (J. INTERFERON RES.) (United States)
1991, 11/4 (221-229)

CODEN: JIRED ISSN: 0197-8357
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/73 (Item 62 from file: 72)

Logon file001 15apr00 10:51:04

*** ANNOUNCEMENT ***

NEW FILE RELEASED

***New Scientit (File 369)

***Newweek Flltext (File 482)

***WIPO/PCT Patent Flltext (File 349)

UPDATING RESUMED

***Bridge World Market New (File 609,809)

***Fort Worth Star-Telegram (File 427)

***Federal New Serice (File 660)

***Kana Cit Star (File 147)

RELOADED

***AIDSLINE (File 157)

***Book in Print (File 470)

***Kompa Latin America (File 586)

>>>Get immediate new with Dialog' Firt Releae
new erice. Firt Releae pdate major newwire

[dialog

databases within 15 minutes of transmission over the
wire. First Release provides full Dialog searchability
and full-text features. To search First Release files in
OneSearch simply BEGIN FIRST for coverage from Dialog's
broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

* * * File 026 is currently unavailable. * * *

File 1:ERIC 1966-2000/Feb

(c) format only 2000 The Dialog Corporation

*File 1: File has been reloaded. See HELP NEWS 1.

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

? b 410

>>>'IALOG' not recognized as set or accession number

? set hi ;set hi

15apr00 10:51:10 User208760 Session D1521.1

\$0.36 0.102 DialUnits File1

\$0.36 Estimated cost File1

\$0.05 TYMNET

\$0.41 Estimated cost this search

\$0.41 Estimated total session cost 0.102 DialUnits

File 410:Chronolog(R) 1981-2000 Mar/Apr

(c) 2000 The Dialog Corporation plc

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

?

HILIGHT set on as ''

HILIGHT set on as ''

? begin 652,653,654

15apr00 10:51:16 User208760 Session D1521.2
\$0.00 0.048 DialUnits File410
\$0.00 Estimated cost File410
\$0.00 Estimated cost this search
\$0.41 Estimated total session cost 0.150 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 652:US Patents Fulltext 1971-1979

(c) format only 2000 The Dialog Corp.

*File 652: Reassignment data current through 12/06/1999 recordings.
Due to recent processing problems, the SORT command is not working.

File 653:US Patents Fulltext 1980-1989

(c) format only 2000 The Dialog Corp.

*File 653: Reassignment data current through 12/06/1999 recordings.
Due to recent processing problems, the SORT command is not working.

File 654:US Pat.Full. 1990-2000/Apr 11

(c) format only 2000 The Dialog Corp.

*File 654: Reassignment data current through 12/06/1999 recordings.
Due to recent processing problems, the SORT command is not working.

Set	Items	Description
---	-----	-----

? s L(w)selectin and polytrauma?

1077019	L
682	SELECTIN
264	L(W)SELECTIN
35	POLYTRAUMA?
S1	0 L(W)SELECTIN AND POLYTRAUMA?

? s L(w)selectin and multiple(w)organ(w)failure

1077019	L
682	SELECTIN
264	L(W)SELECTIN
446437	MULTIPLE
27819	ORGAN
204220	FAILURE
278	MULTIPLE(W)ORGAN(W)FAILURE
S2	3 L(W)SELECTIN AND MULTIPLE(W)ORGAN(W)FAILURE

? t s2/3/all

2/3/1 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03037991

Utility

INHIBITION OF SELECTIN BINDING

PATENT NO.: 5,985,852

ISSUED: November 16, 1999 (19991116)

INVENTOR(s): Nagy, Jon O., Rodeo, CA (California), US (United States of America)
Spevak, Wayne R., Albany, CA (California), US (United States of America)
Dasgupta, Falguni, New Delhi, IN (India)
Bertozzi, Caroline, Albany, CA (California), US (United States of America)

ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), US (United States of America)
[Assignee Code(s): 13234]

APPL. NO.: 9-250,999

FILED: February 16, 1999 (19990216)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of pending U.S. patent application Ser. No. 08-807,428, filed Feb. 28, 1997, which claims priority benefit of U.S. provisional application No. 60-012,894, filed Mar. 1, 1996, both of which are hereby incorporated herein by reference in their entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FULL TEXT: 2032 lines

2/3/2 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03012764

Utility
INHIBITION OF SELECTIN BINDING

PATENT NO.: 5,962,422
ISSUED: October 05, 1999 (19991005)
INVENTOR(s): Nagy, Jon O., Rodeo, CA (California), US (United States of America)
Spevak, Wayne R., Albany, CA (California), US (United States of America)
Dasgupta, Falguni, New Delhi, IN (India)
Bertozzi, Carolyn, Albany, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-807,428
FILED: February 28, 1997 (19970228)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority benefit of U.S. provisional application No. 60-012,894, filed Mar. 1, 1996, pending, which is hereby incorporated herein by reference in its entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FULL TEXT: 2061 lines

2/3/3 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02640574

Utility
CROSS-REACTING MONOCLONAL ANTIBODIES SPECIFIC FOR E- AND P-SELECTIN
[Provides monoclonal antibodies that have binding site that specifically binds to P-selectin and to E-selectin]

PATENT NO.: 5,622,701
ISSUED: April 22, 1997 (19970422)
INVENTOR(s): Berg, Ellen L., Palo Alto, CA (California), US (United States of America)
ASSIGNEE(s): Protein Design Labs, Inc, (A U.S. Company or Corporation), Mountain View, CA (California), US (United States of America) [Assignee Code(s): 25261]
APPL. NO.: 8-259,963
FILED: June 14, 1994 (19940614)
FULL TEXT: 1257 lines
? s L(w)selectin and heart(w)lung(w)machine?

1077019 L
682 SELECTIN
264 L(W)SELECTIN
56295 HEART
23881 LUNG
537544 MACHINE?
799 HEART(W)LUNG(W)MACHINE?
S3 2 L(W)SELECTIN AND HEART(W)LUNG(W)MACHINE?
? t s3/3/all

3/3/1 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03104276

Utility
COMPOSITIONS, METHODS AND DEVICES FOR MAINTAINING AN ORGAN

PATENT NO.: 6,046,046
ISSUED: April 04, 2000 (20000404)
INVENTOR(s): Hassanein, Waleed H., 36 Dartmouth, Apt. 1209, Malden, MA (Massachusetts), US (United States of America), 02148
APPL. NO.: 9-54,698
FILED: April 03, 1998 (19980403)

CROSS-REFERENCE TO RELATED U.S. APPLICATION

The present application is a continuation-in-part of U.S. Ser. No. 08-936,062, filed Sep. 23, 1997, currently pending.

FULL TEXT: 2335 lines

3/3/2 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02993540

Utility
ELECTROPORATION-MEDIATED INTRAVASCULAR DELIVERY

PATENT NO.: 5,944,710
ISSUED: August 31, 1999 (19990831)
INVENTOR(s): Dev, Sukhendu B., San Diego, CA (California), US (United States of America)
Dev, Nagendu B., Cleveland, OH (Ohio), US (United States of America)
Hofmann, Gunter A., San Diego, CA (California), US (United States of America)
ASSIGNEE(s): Genetronics, Inc, (A U.S. Company or Corporation), San Diego, CA (California), US (United States of America)
APPL. NO.: 8-668,725

FILED: June 24, 1996 (19960624)
FULL TEXT: 878 lines
? t s3/k/all

3/K/1 (Item 1 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

OTHER REFERENCES

...Inhibition of Complement Activation Using Recombinant Soluble Complement Receptor 1 On Neutrophil CD11B/CD18 and **L-Selectin** Expression and Release of Interleukin-8 and Elastase In Simulated Cardiopulmonary Bypass," The Journal of...

...body. In this scenario, the patient can be temporarily maintained with a suitable bypass and **heart/lung machine** as is well known in the art. However, removing the heart or any other organ...

3/K/2 (Item 2 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... g., outside the body, while the extracorporeal circulation in the patient is maintained by a **heart-lung machine**, and the vein subsequently grafted by standard methods. Where synthetic material is used as a... leukocytes to the endothelial lining of blood vessels is inhibited by blocking the P- and **L-selectin** receptors, for example.

The dosage ranges for the administration of the compositions in the method...